Generics BulletinHBW InsightIn VivoMedtech InsightPink SheetScrip

Generics Bulletin

Medtech Insight

Biosimilar Guidance Development Timelines Criticized By Docs And Patients

Oct 21 2016

• By Sue Sutter

FDA entrance sign 2016

Related Content

FDA Proposes Dedicated Biosimilar 'Unit' For BsUFA II

May 12 2016

Biosimilars Will Get PDUFA-Style Reviews Under New User Fee Plan

Sep 28 2016

Biosimilar User Fee Agreement Offers FDA Funding Boost, Fee Structure Overhaul

Sep 17 2016

Biosimilar User Fee Agreement Puts FDA On Hook For Delayed Guidances

Sep 22 2016

How Risky Is Pfizer’s Launch Of Its Remicade Biosimilar?

Oct 19 2016

Related Companies

Novartis AG

Amgen, Inc.

Pfizer Inc.

Celltrion, Inc.

Johnson & Johnson

Additional Topics

United States Policy Biosimilars Drug Review BioPharmaceutical

More from Biosimilars

More from Biosimilars & Generics

Twitter feed RSS feed RSS feed

About UsOpens in new window
Meet the TeamOpens in new window
RSS FeedOpens in new window

Contact Us
Customer Service
Subscribe
AdvertisingOpens in new window
Feedback

Terms and ConditionsOpens in new window

Privacy PolicyOpens in new window